-
Front Cardiovasc Med: Biejia Ruanmai Decoction inhibits retinal neovascularization in diabetic mice by inducing apoptosis of retinal vascular endothelial cells
Time of Update: 2022-08-19
Conclusion: BJ inhibited the formation of cell-free capillaries and the instability of retinal structure in the retina of DR mice by inducing cell cycle arrest and reducing mitochondrial membrane potential, inhibited the proliferation of high glucose-exposed HRCECs, and induced apoptosis, indicating that BJ has the potential to treat DR .
-
of retinal neovascularization in patients with proliferative diabetes
Time of Update: 2021-03-22
Recently, studies have explored the distribution of retinal vascular endothelial cells (NV) in patients with proliferative diabetic retinopathy and the local response to Aflibercept (apacilcept, an anti-VEGFF drug) or PRP treatment.
-
that the new coronavirus causes retinal inflammation and affects depth perception
Time of Update: 2023-02-03
The study, which used mice as a model, found that the new coronavirus can infect the brain and eyes through the trigeminal nerve and optic nerve, and cause retinal inflammation and reduced depth perception.
-
"PNAS" artificial retinal cells successfully connected to the eye! Unlock a host of new treatments for eye diseases
Time of Update: 2023-02-03
” David Gamm in his labAccording to a new study, retinal cells grown from stem cells can reach out to connect with neighbors, completing a "handshake," which could indicate that the cells are ready for trials in patients with degenerative eye disease.
-
Aging Cell Stress accelerates retinal degeneration, similar to natural aging
Time of Update: 2023-02-03
A new study in mice by researchers at the University of California, Irvine (UCI) shows that stress, such as elevated intraocular intraocular pressure (IOP), causes epigenetic changes in retinal tissue that resemble natural aging.
-
The retinal research team has made new advances in the early detection of glaucoma visual damage
Time of Update: 2023-02-01
Recently, Professor Wang Zhongfeng, Institute of Brain Sciences/State Key Laboratory of Medical Neurobiology, Fudan University, and Professor Wu Jihong, Department of Ophthalmology, Affiliated Eye, Ear, Nose and Throat Hospital, after more than 3 years of cooperation, have made new progress in the early monitoring of glaucoma visual damage markers, and the research results are based on "A novel biosensing platform for detection of glaucoma biomarker GDF15 via an" integrated BLI-ELASA strategy" was published online in the journal Biomaterials.
-
The new coronavirus causes retinal inflammation by gathering the eye through the trigeminal nerve and optic nerve
Time of Update: 2022-12-30
1038/s41467-022-35225-1The images in the article are from referencesFigure 2: SARS-CoV2 causes an increase in retinal inflammation3SARS-CoV2 infects the eye through the trigeminal and optic nervesTo study the route of SARS-CoV2 infection in the central eye, the researchers infected mice with nasal infection (IN), bronchial infection (IT), ventricular infection (IC), eye infection (ED), and tail vein injection (IV), and found that all other ways can infect the brain except eye infection.
-
J Neuroinflammation—Zhuo Yehong/Su Wenru's team revealed that iron death may be a new mechanism and therapeutic target of retinal ischemia-reperfusion
Time of Update: 2022-11-15
the first time, the researchers constructed a single-cell atlas of retinal ischemia-reperfusion injury in mice, suggesting that targeted inhibition of iron death can effectively protect retinal structure and function.
-
Bispecific antibodies for ophthalmology! Two Phase 3 studies of Vabysmo for retinal vein occlusion (RVO) were successful!
Time of Update: 2022-11-05
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said: "These encouraging data suggest that Vabysmo has the potential to offer a new treatment option for patients with retinal vein occlusion (RVO), a serious retinal vascular disease that can lead to irreversible visual impairment or vision loss.
-
AJNR: neuroimaging of retinal angiopathy with leukoencephalopathy and multisystem damage
Time of Update: 2022-10-19
A 30 mm diameter annular enhancement lesion located on the lateral left frontal horn, with multiple punctate magnetic sensitivity artifacts and diffusion inhibition in the center of the lesion, and peripheral extensive vasogenic edema with mass effect (a, FLAIR.
-
The 3D map reveals DNA tissue within human retinal cells
Time of Update: 2022-10-13
"This is the first detailed integration of the retina-regulatory genomic topology with genetic variants associated with age-related macular degeneration (AMD) and glaucoma, which are two of the main causes of vision loss and blindness," said Anand Swaroop, the study's lead investigator, Dr. Anand Swaroop, senior researcher and director of the NEI Neurodegenerative Degeneration and Repair Laboratory at the National Institutes of Health.
-
The 3D map reveals the DNA tissue within human retinal cells
Time of Update: 2022-10-13
High-resolution genome topology of human retina uncovers super enhancer-promoter interactions at tissue-specific and multifactorial disease loci" by Marchal C, Singh N, Batz Z, Advani J , Jaeger C, Corso-Diaz X, and Swaroop A, 7 October 2022, Nature Communications NIH researchers have revealed new insights into how gene structure determines gene expression, tissue-specific function, and disease phenotypes for blinding diseases.
-
Ther Adv Ophthalmol: Effect of systemic drug selection on prognosis in patients with diabetic central retinal vein obstruction
Time of Update: 2022-10-02
ObjectiveTo evaluate the effect of systemic drug selection and glycemic control on the symptoms, treatment burden and prognosis of diabetic patients who develop central retinal vein occlusion (CRVO).
-
The potential of precise genome editing in the treatment of hereditary retinal diseases
Time of Update: 2022-10-01
Proceedings of the National Academy of Sciences, 2022; 119 (39) In a new paper, researchers at the University of California, Irvine, explain how precision genome editing agents enable precise gene correction and disease rescue in hereditary retinal diseases (IRDs).
-
The potential of precise genome editing in the treatment of hereditary retinal diseases
Time of Update: 2022-10-01
This paper describes current preclinical success and clinical genome editing approaches to the treatment of hereditary retinal degenerative diseases, and highlights the promise that gene editing in living organisms will be the therapeutic paradigm for IRDs in the future.